For Patients


Prostate Cancer Trials

Phase 3 Clinical Trial in 2nd-line Metastatic Castrate-Resistant Prostate Cancer (CRPC)

AFFINITY is a company-sponsored, randomized Phase 3 trial evaluating whether custirsen, when combined with the second-line chemotherapy, Jevtana® (cabazitaxel), has the potential to improve survival outcomes for prostate cancer patients who have progressed following treatment with docetaxel. Patients were randomly selected to receive Jevtana plus prednisone with or without custirsen therapy.

The trial enrolled 634 men with metastatic CRPC and was conducted throughout North America, Europe, Russia and Australia.

Final survival results were announced in August 2016.

Learn more



Phase 2 Clinical Trial in Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Pacific™ is an investigator-sponsored, randomized Phase 2 trial evaluating apatorsen in men with metastatic CRPC who are experiencing rising prostate-specific antigen (PSA) while receiving Zytiga® (abiraterone acetate). Pacific aims to evaluate the potential benefit of adding apatorsen to Zytiga plus prednisone for patients with metastatic CRPC by measuring the treatments’ ability to extend time without disease progression. The trial is sponsored by the Hoosier Oncology Group.

Enrollment completed.


External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue